| BID | 85.61 | ASK | 250.01 | ||
| Open | 210.21 | Previous Close | 206.72 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 286.50 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 35.78 | Finscreener Ranking | ★★ 46.21 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 40.70 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 53.36 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 10.52 | Earnings Rating | Neutral | |
| Market Cap | 17.15B | Earnings Date | 27th Apr 2022 | |
| Alpha | 0.01 | Standard Deviation | 0.07 | |
| Beta | 0.97 |
Today's Price Range 208.45215.58 | 52W Range 199.01313.00 | 5 Year PE Ratio Range 15.3051.00 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.93% | ||
| 1 Month | -14.24% | ||
| 3 Months | -17.53% | ||
| 6 Months | -26.11% | ||
| 1 Year | -8.97% | ||
| 3 Years | 55.06% | ||
| 5 Years | 140.62% | ||
| 10 Years | 856.92% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 8.02 | |||
ROE last 12 Months | 3.40 | |||
ROA (5Y Avg) | 1.59 | |||
ROA last 12 Months | 1.64 | |||
ROC (5Y Avg) | 14.98 | |||
ROC last 12 Months | 3.53 | |||
Return on invested Capital Q | 1.12 | |||
Return on invested Capital Y | 0.33 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 3.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 86.30 | ||||
| 2.26 | ||||
| 2.61 | ||||
| 17.90 | ||||
| -3.60 | ||||
| 12.52 | ||||
| -3.28 | ||||
| 99.26 | ||||
| 22.97B | ||||
| Forward PE | 16.62 | |||
| PEG | 4.74 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.10 | ||||
| 0.39 | ||||
| 0.66 | ||||
| 2.50 | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 27.60 | ||||
| 5.30 | ||||
| 12.00 | ||||
| 13.30 | ||||
| 2.60 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.52B | ||||
| 80.26 | ||||
| 27.25 | ||||
| 24.63 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | 2.48 | 2.60 | 4.84 |
| Q04 2021 | 2.40 | 2.44 | 1.67 |
| Q03 2021 | 2.43 | 2.55 | 4.94 |
| Q02 2021 | 2.10 | 2.12 | 0.95 |
| Q01 2021 | 1.93 | 2.06 | 6.74 |
| Q04 2020 | 1.83 | 1.90 | 3.83 |
| Q03 2020 | 1.55 | 1.72 | 10.97 |
| Q02 2020 | 1.10 | 1.20 | 9.09 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | 2.52 | -76.51 | Negative |
| 9/2022 QR | 2.83 | -77.47 | Negative |
| 12/2022 FY | 10.67 | - | - |
| 12/2023 FY | 12.58 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | 2.48 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | 18.20 |
| Volume Overview | |
|---|---|
| Volume | 519.94K |
| Shares Outstanding | 81.29K |
| Shares Float | 80.16M |
| Trades Count | 10.30K |
| Dollar Volume | 110.67M |
| Avg. Volume | 527.38K |
| Avg. Weekly Volume | 488.89K |
| Avg. Monthly Volume | 466.51K |
| Avg. Quarterly Volume | 626.74K |
ICON plc (NASDAQ: ICLR) stock closed at 211 per share at the end of the most recent trading day (a 2.07% change compared to the prior day closing price) with a volume of 519.94K shares and market capitalization of 17.15B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 15730 people. ICON plc CEO is Steven Cutler.
The one-year performance of ICON plc stock is -8.97%, while year-to-date (YTD) performance is -31.87%. ICLR stock has a five-year performance of 140.62%. Its 52-week range is between 199.01 and 313, which gives ICLR stock a 52-week price range ratio of 10.52%
ICON plc currently has a PE ratio of 86.30, a price-to-book (PB) ratio of 2.26, a price-to-sale (PS) ratio of 2.61, a price to cashflow ratio of 17.90, a PEG ratio of 2.32, a ROA of 1.64%, a ROC of 3.53% and a ROE of 3.40%. The company’s profit margin is 2.60%, its EBITDA margin is 12.00%, and its revenue ttm is $6.52 Billion , which makes it $80.26 revenue per share.
Of the last four earnings reports from ICON plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.48 for the next earnings report. ICON plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for ICON plc is Moderate Buy (1.75), with a target price of $286.5, which is +35.78% compared to the current price. The earnings rating for ICON plc stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ICON plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ICON plc has a Sell technical analysis rating based on Technical Indicators (ADX : 15.21, ATR14 : 10.35, CCI20 : -87.74, Chaikin Money Flow : -0.13, MACD : -8.27, Money Flow Index : 47.47, ROC : -1.93, RSI : 38.99, STOCH (14,3) : 34.73, STOCH RSI : 0.47, UO : 39.42, Williams %R : -65.27), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ICON plc in the last 12-months were:
ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
CEO: Steven Cutler
Telephone: +353 12912000
Address: South County Business Park, Dublin 18, , IE
Number of employees: 15 730
TipRanks News for ICLR
Sat, 30 Apr 2022 03:55 GMT Icon (ICLR) Gets a Buy Rating from Robert W. Baird
- TipRanks. All rights reserved.Mon, 21 Mar 2022 12:35 GMT Analysts Offer Insights on Healthcare Companies: Icon (ICLR), United Therapeutics (UTHR) and Legend Biotech (LEGN)
- TipRanks. All rights reserved.Sat, 05 Mar 2022 09:01 GMT Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), IDEAYA Biosciences (IDYA)
- TipRanks. All rights reserved.Thu, 27 Jan 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Icon (ICLR) and PDS Biotechnology (PDSB)
- TipRanks. All rights reserved.Wed, 19 Jan 2022 12:36 GMT Icon (ICLR) Gets a Buy Rating from Mizuho Securities
- TipRanks. All rights reserved.
